Patent 9139580 was granted and assigned to Genzyme on September, 2015 by the United States Patent and Trademark Office.
The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.